Podcasts about Royal North Shore Hospital

In this second part of TOGA's Conversations in Lung Cancer Research two-episode series, A/Prof Adnan Nagrial, a Medical Oncologist at Westmead Hospital, leads a panel discussing the clinical implications of the March 1st broad Pharmaceutical Benefits Scheme (PBS) listing of ipilimumab and nivolumab in Australia. Joined by Prof Nick Pavlakis (Senior Staff Specialist at Royal North Shore Hospital, Professor of Medicine at the University of Sydney, former chair of TOGA), Dr. Sam Bowyer (Medical Oncologist at Sir Charles Gairdner Hospital and Clinical Researcher at Linear Clinical Research) and Dr. Lavinia Tan (Medical Oncologist at Peter MacCallum Cancer Centre), the conversation explores how this newly granted flexibility alters treatment paradigms across various thoracic malignancies, including non-small cell lung cancer (NSCLC), mesothelioma, small cell lung cancer (SCLC), and rare thymic tumours while also addressing toxicity management and the growing demands of patient survivorship. Podcast Sponsor Note: This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. (00:00) Welcome and Acknowledgement (01:33) Panel Introductions (02:52) First Reactions in Clinic (05:01) Frontline NSCLC Evidence (06:48) Who Gets Ipi Nivo? (11:29) Chemo Free and Rechallenge (15:20) Stopping or Continuing IO (20:34) Mesothelioma Treatment Choices (27:20) Small Cell Reality Check (30:21) Thymic Malignancies Debate (34:54) Governance and Toxicity Safety (38:44) Survivorship and Follow Up (43:43) Real World Data Next Steps (48:05) Wrap Up Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

This episode explores the rapidly evolving landscape of lung cancer treatment, from the removal of stigma in general practice to the emergence of targeted therapies, immunotherapy, and precision medicine. The panel discusses the critical role of the multidisciplinary team — particularly cancer nurses — in treatment coordination, toxicity management, and patient education, with a focus on meeting patients where they are across diverse cultural, social, and clinical backgrounds. Hosted by Melanie Rabbets, Oncology Nurse Practitioner at Blacktown Cancer Care, Western Sydney, and joined by Associate Professor Mal Itchins, Medical Oncologist and trialist at Royal North Shore Hospital and Chris O'Brien Lifehouse, Sydney, and Dr Renae Grundy, Lung Cancer Clinical Nurse Consultant at Royal Hobart Hospital, Tasmania. Sponsored by Pfizer.

In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Malinda Itchins, a medical oncologist and clinician researcher at Royal North Shore Hospital and Chris O'Brien Lifehouse , leads a practical overview of managing thymic cancers in Australia and New Zealand. She is joined by an expert panel featuring Prof Steven Kao, a thoracic medical oncologist at Chris O'Brien Lifehouse, Dr. Felicity Meikle, a cardiothoracic surgeon at the Waikato District Health Board in Hamilton, and Dr. Dasantha Jayamanne, a radiation oncologist at Royal North Shore Hospital and Genesis Care in Sydney. Despite being a "forgotten area" in thoracic oncology, these rare tumours remain a key focus for research and multidisciplinary care. (00:00) Introducing the Topic and Experts (02:10) Epidemiology and Risk Factors (04:26) Symptoms and Initial Workup (06:40) PET Scans and Biopsy Decisions (11:40) Pathology and Staging Basics (15:05) MDT Strategy (16:08) Postoperative Treatment (19:46) Perioperative Systemic Therapy (23:08) Stage IV Management and Surgery (25:47) Immunotherapy in Thymic Carcinoma (34:51) Next Line and Targeted Options (42:04) Wrap Up and Thanks Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

In this episode, we're joined by Dr Mariya Farah Kitson, Consultant Rheumatologist at the Osteoporosis Refracture Prevention Clinic at Royal North Shore Hospital, for a deep dive into the diagnosis and management of osteoporosis. We explore why osteoporosis remains significantly underdiagnosed, current recommendations for bone mineral density (BMD) screening, and the ongoing osteoporosis care gap that leaves many patients untreated after fragility fractures. Dr Kitson also explains the role of secondary fracture prevention services and why menopause represents a particularly high-risk period for accelerated bone loss and fracture risk in women. The conversation also unpacks the evolving treatment landscape for osteoporosis, including discussions around denosumab, its PBS and other indications, and important considerations regarding duration of therapy and rebound vertebral fracture risk following discontinuation. Dr Kitson compares the mechanisms of action of denosumab and bisphosphonates, outlines current recommendations for safely stopping denosumab, and discusses where newer therapies such as romosozumab fit into contemporary osteoporosis care. We also touch on the emerging role of biomarkers in fracture risk assessment and treatment monitoring, offering listeners an up-to-date and clinically relevant overview of osteoporosis management.   Further Links  ASBMR - The American Society for Bone and Mineral Research - https://www.asbmr.org/Default.aspx  International Osteoporosis Foundation https://www.osteoporosis.foundation/ 

In this episode of 'Conversations in Lung Cancer Research,' hosted by Associate Professor Mal Itchens, a multidisciplinary panel delves into the ongoing advancements in lung cancer research in Australia and New Zealand. The panel includes Professor Nick Pavlakis from Royal North Shore Hospital and Associate Professor Lauren Troy from Royal Prince Alfred Sydney. Key topics discussed include the 2025 lung cancer screening program, anticipated pharmaceutical benefits scheme (PBS) drug listings for 2026, and the introduction of advanced diagnostic technologies. The conversation highlights the initial impacts of the lung cancer screening program, potential benefits of new ALK inhibitors, and the expanding role of immunotherapy. The episode also explores the future of diagnostic precision with the rise of interventional pulmonology and liquid biopsies. Additionally, it emphasises the growing importance of specialised lung cancer nursing and the integration of novel technologies in oncology practices.00:00 Introduction to Lung Cancer Research Podcast00:37 Panel Introduction and Discussion Overview01:18 Lung Cancer Screening in Australia02:30 Impact of Screening on Diagnostic Services06:45 Screening Program Benefits and Challenges10:34 Future of Lung Cancer Screening15:54 Advancements in Diagnostic Technology20:57 Therapeutic Developments in Lung Cancer24:34 New Drug Listings and Their Impact40:04 Immunotherapy and Future Directions44:13 Conclusion and Final Thoughts  

In this bonus recap episode, Nikki shares all about the lead up to her wedding - from her amazing hens to an unexpected challenge when her dad needed gallbladder surgery just after arriving from the UK. She reflects on the celebrations with Nick and their loved ones in Fiji, and the moments that made it all so special. Special mentions to:Royal North Shore Hospital - https://www.nslhd.health.nsw.gov.au/RNSH/Pages/default.aspxSofitel Fiji - https://www.sofitel-fiji.com/Virgin Australia - https://www.virginaustralia.com/au/en/Kendell Tyne Photography - https://www.kendelltynephotography.com/Moira Hughes Bridal (Wedding Dress) - https://moirahughes.com.au/Faika Karim (Wedding Eve Dress) - https://www.instagram.com/faikacollection/?hl=enLaher (Rings) - https://laher.co/MJ Bale (Suits) - https://www.mjbale.com/Country Road (Boys Outfits) - https://www.countryroad.com.au/William Lee (DJ) - https://www.instagram.com/djwillfj/?hl=en Hosted on Acast. See acast.com/privacy for more information.

The FiltrateJoel Topf @kidneyboy.bsky.social‬Swapnil Hiremath @hswapnil.medsky.socialNayan Arora captainchloride.bsky.socialSopia Ambruso @sophia-kidney.bsky.socialSpecial Guests Brendon Neuen @brendonneuen.bsky.social Associate Professor and Program Lead, Renal and Metabolic at The George Institute for Global Health. Nephrologist and Director of Kidney Trials at Royal North Shore Hospital.Neuen has had three prior appearances on Freely Filtered: EMPA Kidney, DUPLEX and Sparsentan in FSGS, FLOW and SemaglutideMuthiah Vaduganathan @mvaduganathan on X. Cardiologist at Brigham and Women's Hospital and Harvard Medical School. Assistant Professor of Medicine.Editing byJoel TopfThe Kidney Connection written and performed by Tim YauShow NotesDONATE to NephJC! Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes NEJM | NephJC SummaryFIDELIO Bakris et al, NEJM 2020 | NephJC Summary; subgroup throws doubt on efficacy of finerenone in patients on flozinsFIGARO Pitt et al, NEJM 2021; subgroups clearly shows finerenone works, flozins or notNEJM editorial (wrongly) saying do not use Flozins unless on RASi Don't use dual RAS blockade ONTARGET Yusuf et al, NEJM 2008; VA NEPHRON-D Fried et al NEJM 2013Why we cannot study finerenone in HFrEF (RALES Pitt et al NEJM 1999) Muthu is jealous of GFR slope and albuminuria surrogate endpoints and wants to borrow them for HFpEF (Inker et al EHJ 2025)Combination therapy and CV outcomes in hypertension (Wang et al JAMA Card 2024 on low dose combinations and BP; Egan et al Blood Pressure 2022 review of topic) CONFIRMATION HF trial registry entry (Finerenone and Empagliflozin in hospitalized patients with HF)23:20: Nayan and Swap miss a chance to say ‘de-flozination' to discuss stopping a flozin which would allow a patient to be included in the trial Finerenone is a CYP3A4 substrate (Heinig et al Clin Pharmacokinetics 2023); Useful list of CYP3A4 inducers and inhibitors Everyone should get an ABPM (Bugeja et al CMAJ 2022)EASiKIDNEY study design Albuminuria mediates CKD benefits with Finerenone (Agarwal et al Ann Intern Med 2023)GFR slope and Albuminuria and the FDA (Taylor et al eClin Med 2025) Dapagliflozin and Eplerenone combination crossover trial (Provenzano et al JASN 2022)Joel gets promoted! (PBFluids reflection) Bluesky NephJC Chat discussion on ‘renal remission' Withdrawal of Finerenone and worse outcomes from FINEARTS (Vaduganathan et al JACC 2025)Combination therapies Analysis from Brendan and Muthu (Neuen et al Circulation 2024)Do not use KFRE when GFR > 60 (KDIGO Practice Point 2.2.4: Note that risk prediction equations developed for use in people with CKD G3–G5, may not be valid for use in those with CKD G1–G2) Finerenone vs Spironolactone trial in Primary Aldosteronism (Hu et al Circulation 2025)FIND CKD trial design (Heerspink et al NDT 2025) FINE-ONE trial design (Heerspink et al Diab Res Practice 2023) Tubular SecretionsNayan keeping his chin up as Yankees lose and Mariners follow (MLB Playoffs)Sophia's adventures with Beekeeping (Royal Jelly?) Brendon loves listening to ‘Susan' by Raye Muthu is back into Taekwondo Swap is still reading Martha Wells (Witch King on GoodReads)Joel will be hiking the Laugavegur trail in Iceland

Today we discuss living with metastatic ovarian cancer and how as Nurses, we can support our patients transitioning to oral maintenance therapies. Lisa Peterson, CNC at GenesisCare St Leonards in Sydney, is joined by Dr. Sally Baron Hay, medical oncologist at Royal North Shore Hospital, North Shore Private Hospital, the Mater Hospital, Sydney and Esther White, CNC Cancer Care Coordinator at the Mater in Brisbane. https://www.cnsa.org.au/

In a special series dedicated to the Australian Clinical Entrepreneur Program (AUSCEP) we introduce you to some of the passionate health professionals taking part in this 12-month program to develop their innovative ideas into products and enterprises.Dr Yagiz Aksoy is a Resident Doctor at Royal North Shore Hospital in Sydney and co-founder and Director of EosGene Therapeutics, a startup developing a pioneering light-activated gene therapy for diabetic retinopathy and macular degeneration using proprietary drug delivery technology – removing the need for painful eye injections.Yagiz explains how taking part in AUSCEP helped him shift from being a clinician researcher to becoming a translational founder, giving him the language and tools to navigate startup strategy. And it gifted him a community of clinicians trying to solve real problems in different ways.The program's third cohort has been delivered in NSW and Victoria, in partnership with MTPConnect and Australian Society for Medical Entrepreneurship and Innovation (ASME) and supported by LaunchVic and NSW Agency for Clinical Innovation (ACI). The next 2025/26 cohort is open for Victorian applications until 20 June 2025 – apply at auscep.au.This episode is hosted by MTPConnect's Caroline Duell and Elizabeth Stares.

In this piece we discuss prevention of intraoperative hypothermia with Holly Tonkin, a trainee anaesthetist from Australia. Holly describes her study, in which she measured the prevalence of hypothermia using routine forced air warming and then the prevalence using the 3M™ Bair Hugger™ Universal Warming Gown. Significant reductions in hypothermia were observed. Holly's study was supported by Solventum. We then discussed the value of trainee research. Presented by Andy Cumpstey and Kate Leslie on location at the Annual Scientific Meeting of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine in Cairns, Australia, with their guest, Dr Holly Tonkin, Manning Base Hospital and Royal North Shore Hospital, New South Wales, Australia.

We never thought we'd see the day that a doctor joined us on the pod, and to be honest, we couldn't be more grateful to have Dr. Kieran McCaffrey with us. Having trained at Royal North Shore Hospital, Dr. McCaffrey is an obstetrician and gynaecologist. Fun fact: he is one of 11 children (10 boys, 1 girl). Yes, you heard that correctly. His dad is an OB, and two of his brothers are also doctors. Genius genes!We asked Dr. McCaffrey every question under the sun about pregnancy and birth, including (but not limited to): when to take your undies off (vitally important), how to limit interventions, managing mental health and migraines during pregnancy, forceps delivery, low-lying placenta, an en caul baby (yep, that's French for "under the veil" for you non-bilingual folks), what a teratoma is, and everything in between.We hope you enjoy!Kolide Advice || Dr McCaffrey || Baby Bible + Hydra MamaElla || Watch VigilSteph || Drink / Eat || Lox in Box Matcha + Cookies Hosted on Acast. See acast.com/privacy for more information.

In this episode, we discuss the clinical and diagnostic markers when identifying a rare sub type of NSCLC, large-cell neuroendocrine carcinomas (LC-NEC), and provide insights into the management of these patients and future treatment developments. Associate Professor Rachel Wong, Deputy Director Oncology Eastern Health and Medical Oncologist at Epworth East in Melbourne is joined by Dr Patrick Hosking, Senior Histopathologist at Eastern Health Pathology; Dr Mal Itchins, Thoracic Medical Oncologist at Royal North Shore Hospital and Chris O'Brien LifeHouse in Sydney and Dr Sagun Parakh, Medical Oncologist at the Austin Hospital, Lung Cancer Lead. https://www.omico.com.au/our-programs/cancer-screening-program-casp/

In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a discussion about the management of relapsed SCLC, which remains a very challenging cancer to treat, despite recent progress. Guest: Dr. Malinda Itchins is a Medical Oncologist at Royal North Shore Hospital, Visiting Medical Officer for Thoracic Cancers at Chris O'Brien Lifehouse, and Faculty at the University of Sydney. She is the Board Director and Lung Cancer Chair for the Clinical Oncology Society of Australia (COSA) and the Scientific Committee Advanced NSCLC Group Co-Chair for the Thoracic Oncology Group of Australasia (TOGA). Guest: Dr. Jacob Sands is an Assistant Professor at Harvard Medical School and Thoracic Medical Oncologist at the Lowe Center for Thoracic Oncology at the Dana Farber Cancer Institute, where he leads the Clinical Research Program in SCLC. Jacob is also Co-founder and President of the Rescue Lung Society, a 501(c)3 society focused on advancing lung cancer screening.

This is the first in the four-part series on anatomical trauma with some of the world's leading experts on specialist pre-hospital care. In today's episode, we delve into the complexities of assessing and treating thoracic injuries in pre-hospital care. We'll cover a range of topics, including pneumothorax, haemothorax, and flail chest. Our discussion will span the primary and secondary survey, airway management considerations, and the efficacy and evolution of modern interventions such as needle decompression. To bring these concepts to life, we'll examine real-life cases that highlight the challenges faced by healthcare professionals in the field. Joining me is Geoff Healey, a distinguished Prehospital and Retrieval Physician with Sydney HEMS. Geoff also serves as a Consultant Anaesthetist at Royal North Shore Hospital in Sydney and the Deputy Medical Manager for Sydney HEMS. With extensive experience in Australia's and the UK's Prehospital and Retrieval Systems, Geoff brings invaluable insights into our conversation. Additionally, he is an active member of the NSW Taskforce Urban Search and Rescue Team and has been deployed on numerous humanitarian missions worldwide. We unpack the intricacies of thoracic trauma management in pre-hospital settings, guided by Geoff's expert knowledge and frontline experiences.

With 18 years' experience working across health, science, education and research projects at BVN, Conor Larkins will head up HDR's health sector and work with directors to elevate the practice's design rigour and deliver human-centred facilities.  Larkins has worked across many of Australia's most significant health precincts, including Prince of Wales Acute Services Building, the Lang Walker AO Medical Research Building, Nepean Hospital Redevelopment, Royal North Shore Hospital, and Northside Hospital in Canberra. In this exclusive interview, we talk about how designers prioritize resilience in healthcare design, and how to enable facilities to readily respond to disruptions, big and small, and adapt as needs evolve. This Podcast was brought to you by Siniat, proud sponsors of our 2024 Aged & Healthcare series.

Do we need to evolve the bar on evidence required for drug reimbursement? The gold standard endpoint for assessing the benefit of anti-cancer drugs has been overall survival (OS) however, more recently, there has been a trend toward using surrogate clinical trial endpoints such as progression free survival (PFS) and event-free survival (EFS). As treatments improve and patients are living longer, using OS as a primary endpoint can mean a longer time until a result is obtained. In this podcast, Dr Rebecca Tay, Medical Oncologist at Royal Hobart Hospital and ICON, discusses the critical role of improvement in quality of life in assessing drugs that are funded on the PBS, the nuances around clinical trial endpoints and the need for surrogate endpoints that accurately predict for OS and a reimbursement system that brings beneficial treatments to patients faster. Professor Nick Pavlakis, Chair of TOGA and Medical Oncologist at Royal North Shore Hospital and Genesis Care and Dr Deme Karikios, Immediate Past Chair of MOGA and Medical Oncologist from Nepean Hospital Sydney join the conversation. https://jamanetwork.com/journals/jama/article-abstract/2817337

In this episode of ‘Safeguarding Healthcare', Dr David Rankin delves into the complexities of medical administration with guest Dr Bahare Moradi, the Acting Director of Medical Services at the Royal North Shore Hospital in northern Sydney. Together, they dissect a common scenario involving a surgical registrar facing a challenging appendectomy. Dr Moradi highlights the delicate balance between patient safety and providing learning experiences for trainees, emphasising the need for structured support systems within hospitals. They discuss strategies for ensuring young doctors seek help when needed and navigating the dynamics between junior and senior staff. Disclaimer: The views, thoughts, and opinions expressed in the following Podcast are the speaker's own and do not represent the views, thoughts, and opinions of the Royal Australasian College of Medical Administrators (RACMA). The material and information presented here is for general information purposes only, and should not be considered health, legal or financial advice. The cases discussed in the Podcast may be specific to the speaker's organisation or location, and may not be applicable to other organisations, states, territories or countries. RACMA does not endorse, approve, recommend, or certify any information, product, process, service, or organisation presented or mentioned in this Podcast, and information from this Podcast should not be referenced in any way to imply such approval or endorsement. RACMA will not be held responsible for any losses, damages, or liabilities that may arise from the use of this Podcast. The Podcast may contain descriptions of health incidents that may be graphic and triggering for some people, so listener discretion is advised.See omnystudio.com/listener for privacy information.

Neoadjuvant immunotherapy is transforming patient care in the field of melanoma. New research recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting is set to change melanoma treatment protocols globally, and likely to have significant impact on treatment for other cancers too. In this podcast, A/Prof Matt Carlino leads an engaging discussion with MIA's Prof Georgina Long AO, A/Prof Alex Menzies and A/Prof Alex van Akkooi as they discuss the pivotal results from the NADINA trial and how this will undoubtedly change the standard of care for Stage III melanoma patients. They also discuss the practical implications for implementing this treatment regime, including relevant patient populations, toxicity, impacts for surgery and future directions. This podcast is suitable for Medical Oncologists, Surgical Oncologists, Pathologists, Researchers, GPs Oncology Nurses and other healthcare professionals. It is produced by Melanoma Institute Australia. SPEAKERS A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney PUBLICATIONS Blank C, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med 2024. DOI: 10.1056/NEJMoa2402604 Patel SP, Othus M, Chen Y, et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023;388:813-823. FURTHER EDUCATION Podcast: Neoadjuvant immunotherapy: Revolutionising melanoma treatment Video: The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists Conference: 2024 Australasian Melanoma Conference Please note that this podcast was accurate at the time of recording (2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA's Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

On this week's episode we are super excited to be introducing you to our next special guest Host and Social Worker, Jessica Bakon. Jessica is a qualified Social Worker who holds an (Honours) degree from the University of New South Wales. As a new graduate, she worked across both private and public hospitals within the Northern Sydney Local Health District such as at Royal North Shore Hospital. This is where Jessica found passion in utlising evidence- based treatments with patients such as Narrative Therapy, Cognitive Behavioural Therapy and Solution Focused Therapy. Jessica was also trained at Royal North Shore Hospital as a student and had the opportunity of working for BodyMatters Australasia, on her second University internship. This is where Jessica was offered the incredible opportunity to host and produce the ‘Understanding Body Matters Podcast' after the podcast was so beautifully started and crafted by Madison Prubela. Where Jessica has been able to be involved in sharing stories of hope, lived experience, education, professional development, advocacy, wellbeing content and awareness for eating disorders. After a year of working within the healthcare system and gaining the experience she was hoping for Jessica has now gone back to University to complete her Masters of Counselling and Psychotherapy. Hoping to support people in the field of eating disorders and within schools with a special interest for working with adolescents.   A little background about Jessica, she grew up on the Northern Beaches and spent her young working years enjoying her studies, volunteering for charities, and finding a passion in supporting people. However, during her teen years Jessica found herself impacted by disordered eating as a result of an adverse early childhood, social influences and the impact of diet culture. That is why on this week's episode our Host Jessica will be sharing her story with disordered eating, her upbringing, and the reason for her passions in hosting the ‘Understanding Body Matters Podcast'. Jessica also shares the details of how receiving required support, addressing the adverse childhood experiences and having positive role models in her life really helped her along her journey.   In this week's episode Jessica will also disclose brief elements of family domestic violence, strength, and success despite significant challenges faced. Where Jessica thanks the many guests on the podcasts who have been so vulnerable in being able to provide awareness for eating disorders, mental health, and overall wellbeing. This is where Jessica shares her value for learning, education, teachers, supervisors, mentors, and positive role models within her life. As the support from these people were all the main components of Jessica being able to be the person she is today. As someone who now loves and values the role that food can have in her life Jessy now shares her story of gratitude for her recovery and the appreciation that she has for her life. So, on that note, please welcome our next special guest host, Jessy!   Podcast Summary   1.    The impact of adverse childhood experiences 2.    Friendships with people who engaged in disordered eating 3.    Learning to drink alcohol in a binge drinking culture in Australia   4.    Transitional periods 5.    The power of support, role modelling and positive people 6.    Education, awareness, and advocacy in eating disorders  BodyMatters Australasia Website: ⁠⁠⁠⁠⁠⁠⁠https://bodymatters.com.au/⁠⁠⁠⁠⁠⁠⁠ BodyMatters Instagram: @bodymattersau Butterfly Foundation Helpline: Call their National Helpline on ⁠⁠⁠⁠⁠⁠⁠1800 33 4673⁠⁠⁠⁠⁠⁠⁠. You can also ⁠⁠⁠⁠⁠⁠⁠chat online⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠email

On this week's episode we are super excited to be introducing you to our next special guest Host and Social Worker, Jessica Bakon. Jessica is a qualified Social Worker who holds an (Honours) degree from the University of New South Wales. As a new graduate, she worked across both private and public hospitals within the Northern Sydney Local Health District such as at Royal North Shore Hospital. This is where Jessica found passion in utlising evidence- based treatments with patients such as Narrative Therapy, Cognitive Behavioural Therapy and Solution Focused Therapy. Jessica was also trained at Royal North Shore Hospital as a student and had the opportunity of working for BodyMatters Australasia, on her second University internship. This is where Jessica was offered the incredible opportunity to host and produce the ‘Understanding Body Matters Podcast' after the podcast was so beautifully started and crafted by Madison Prubela. Where Jessica has been able to be involved in sharing stories of hope, lived experience, education, professional development, advocacy, wellbeing content and awareness for eating disorders. After a year of working within the healthcare system and gaining the experience she was hoping for Jessica has now gone back to University to complete her Masters of Counselling and Psychotherapy. Hoping to support people in the field of eating disorders and within schools with a special interest for working with adolescents.   A little background about Jessica, she grew up on the Northern Beaches and spent her young working years enjoying her studies, volunteering for charities, and finding a passion in supporting people. However, during her teen years Jessica found herself impacted by disordered eating as a result of an adverse early childhood, social influences and the impact of diet culture. That is why on this week's episode our Host Jessica will be sharing her story with disordered eating, her upbringing, and the reason for her passions in hosting the ‘Understanding Body Matters Podcast'. Jessica also shares the details of how receiving required support, addressing the adverse childhood experiences and having positive role models in her life really helped her along her journey. In this week's episode Jessica will also disclose brief elements of family domestic violence, strength, and success despite significant challenges faced. Where Jessica thanks the many guests on the podcasts who have been so vulnerable in being able to provide awareness for eating disorders, mental health, and overall wellbeing. This is where Jessica shares her value for learning, education, teachers, supervisors, mentors, and positive role models within her life. As the support from these people were all the main components of Jessica being able to be the person she is today. As someone who now loves and values the role that food can have in her life Jessy now shares her story of gratitude for her recovery and the appreciation that she has for her life. So, on that note, please welcome our next special guest host, Jessy!   Podcast Summary: 1. The impact of adverse childhood experiences 2. Friendships with people who engaged in disordered eating 3. Learning to drink alcohol in a binge drinking culture in Australia   4. Transitional periods 5. The power of support, role modelling and positive people 6. Education, awareness, and advocacy in eating disorders Links from the episode and to BodyMatters: BodyMatters Australasia Website: ⁠⁠⁠⁠⁠⁠⁠https://bodymatters.com.au/⁠⁠⁠⁠⁠⁠⁠ BodyMatters Instagram: @bodymattersau Butterfly Foundation Helpline: Call their National Helpline on ⁠⁠⁠⁠⁠⁠⁠1800 33 4673⁠⁠⁠⁠⁠⁠⁠. You can also ⁠⁠⁠⁠⁠⁠⁠chat online⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠email

Mucosal melanoma is a rare and aggressive form of melanoma that arises from the mucous membrane. In this podcast, we focus on mucosal melanoma of the head and neck. Led by A/Prof Sydney Ch'ng, our multidisciplinary experts discuss how it differs from cutaneous melanoma, staging of mucosal melanoma, management of the disease and future treatments. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, Surgical Oncologists, Dermatologists, Medical Oncologists, Pathologists, GPs, Nurses and other healthcare professionals. SPEAKERS A/Prof Sydney Ch'ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Raewyn Campbell - Rhinologist and Anterior Skull Base Surgeon |Associate Professor, Macquarie University Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney Please note that this podcast was accurate at the time of recording (March 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA's Education Program is proudly supported through unrestricted educational grants from MSD, BMS and HEINE.

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives hosts are joined by Brendon Neuen, MBBS, PhD, nephrologist and director of the Kidney Trials Unit at Royal North Shore Hospital and senior research fellow at The George Institute for Global Health. During the episode, Neuen talks about the FLOW trial, topline results, how the rapid advancement in pharmacotherapies has altered conversations around management, the concept of 4 pillars of GDMT for CKD in type 2 diabetes, and how to approach sequencing of these therapies. Video Version: https://www.hcplive.com/view/diabetes-dialogue-flow-trial-and-chronic-kidney-disease-updates-with-brendon-neuen-mbbs-phd Episode Highlights 00:32 - Neuen Introduction 01:55 - FLOW Trial 05:15 - Pillars of CKD Therapy 16:15 - Need for New Guidelines 21:15 - Barriers to Uptake 24:50 - Need for Screening

The process of identifying which patients with acute myeloid leukemia (AML) can benefit from allogeneic stem cell transplantation in first complete remission (CR1) has taken a step forward thanks to analysis of the UK NCRI AML17 and AML19 studies, reported at the 65th ASH Annual Meeting and Exposition. Patients who achieved molecular residual disease (MRD) negativity in their peripheral blood were at low risk of relapse, and had no benefit from allogeneic transplant in CR1, including those with the FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication mutation of the NPM1 (nucleophosmin 1) gene, that is generally considered to be a marker of poor risk. Peter Goodwin spoke with Jad Othman, MBBS, from King's College London and the Guy's and St Thomas' Hospital in London, and now based at the Royal North Shore Hospital in Sydney, Australia. Othman explained how testing for the FLT3 mutation of the NPM1 gene can be used along with assessment of molecular MRD to help choose patients who can benefit from transplant and spare those for whom the risk/benefit ratio is adverse.

Jonathan is joined by Simon Fleming, orthopaedic surgeon, Royal North Shore Hospital, Sydney, Australia, and Fellow of the Royal College of Surgeons of England. Passionate about improving the quality and culture of healthcare, Simon discusses advocating for increased education standards, and his groundbreaking work to drive out bullying, discrimination, and harassment in healthcare.   Use the following timestamps to navigate the content in this episode:   (00:00)-Introduction  (02:12)-Fleming the orthopod   (08:05)-Training and practicing in Britain and Australia  (13:40)-Similarities and dissimilarities  (15:56)-Rocking the boat   (21:28)-Bullying and discriminatory behaviours in healthcare  (23:11)-The BOTA census  (26:09)-TEDx NHS  (29:14)-Holding sexual predators accountable   (34:00)-Pronouns  (37:35)-#OrthoTwitter   (40:35)-Flawed assessment in healthcare  (43:46)-Influencing the next generation  (46:36)-Three wishes for the future of healthcare 

In this Creative Careers in Medicine podcast episode, Dr Elise Putt speaks with Dr Jo Braid, who reflects on her career journey as a rehabilitation medicine physician and a burnout recovery coach.Dr Braid, operating out of Orange, New South Wales, splits her time between the Central West Brain Injury Rehabilitation Programme and her coaching business. Her medical practice is centred on aiding those with traumatic brain injuries to regain their roles in the community, while her coaching focuses on guiding healthcare workers through burnout.Within her varied schedule, Dr Braid consults biweekly at Bathurst Health Service, coaches around ten clients weekly, and manages her podcast and administrative duties. Tennis remains a consistent part of her life, anchoring her weekly routine.Her medical career, prompted by her uncle's encouragement, commenced at Nottingham Medical School. Her journey took her from the UK to Sydney's Royal North Shore Hospital, driven by familial ties to Australia and a quest for a balanced lifestyle. Although initially drawn to anaesthesia, the hands-on nature and calmer pace of rehabilitation medicine steered her path.Dr Braid's pivot to rehabilitation medicine and subsequent experience with burnout in her clinic led to a career-defining shift during the pandemic, culminating in her coaching and podcasting ventures from October 2021.Dr Braid's shift to coaching and podcasting shows her strength and ability to enjoy different kinds of work in medicine. Her dedication to helping people get over burnout highlights her as a guiding light for healthcare workers looking at different career paths.To get more CCIM, subscribe so you never miss an episode, join our Facebook community and subscribe to our newsletter!Website: https://creativecareersinmedicine.com/Facebook: https://www.facebook.com/CreativeCareersInMed/The CCIM Podcast is a proud member of the Talking HealthTech Podcast Network - the premier audio destination for cutting-edge insights and thought leadership in healthcare delivery, innovation, digital health, healthcare ICT, and commercialisation. Learn more at www.talkinghealthtech.com/podcast/network.

On this week's special episode hear from experts in weight loss and osteoarthritis, including content from: Stephen Messier - Losing weight and osteoarthritis– why and how? (Season 1, Episode 4)Rosie Venman - Implementing dietary change (Season 1, Episode 20)Stephen Messier has been at Wake Forest University for 36 years. He is the Director of the J.B. Snow Biomechanics Laboratory and teaches undergraduate biomechanics and human gross anatomy as well as graduate biomechanics. Dr. Messier has 26 years of clinical trial experience concerning osteoarthritis (OA) of the knee; his team of clinicians and researchers are recognized for their research regarding the effects of weight loss and exercise upon knee OA pain, function, strength, and gait biomechanics.Rosie Venman is a clinical Dietitian working at Royal North Shore Hospital. Rosie received her Bachelor's degree in Food Science and Human Nutrition from the University of Newcastle and a Masters in Nutrition and Dietetics from Sydney University. At Royal North Shore Hospital she has been working as the Osteoarthritis Chronic Care Program Dietitian for the last 4 years and has a keen interest in improving weight loss outcomes for this patient group.CONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcast Hosted on Acast. See acast.com/privacy for more information.

Professor Christopher Little is director of the Raymond Purves Bone and Joint Research Labs at the Kolling Institute of Medical Research at Royal North Shore Hospital, Australia. Chris is a qualified Veterinarian with specialist surgery training and ACVS certification. Chris's research interests focus on defining the biochemical and molecular mechanisms of joint pathology in OA, and tendon and intervertebral disc degeneration, and are based on the belief that it is only though a better understanding the mechanisms that drive the initiation and progression of these diseases that new therapies can be developed. Chris is recognized internationally for his expertise in the development and use of animal models of bone and joint disease.CONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

Sentinel node biopsy (SNB) plays a key role in assessing the prognosis of melanomas. In this fireside chat from our new SNB Training Program (Sentinel Node Biopsy: From guidelines to practice), MIA's Prof Georgina Long AO, Prof John Thompson AO and A/Prof Sydney Ch'ng discuss: the history of SNB in the management of melanoma its current role in the stratification of patients into those who may benefit from adjuvant therapies verses those for whom active surveillance is more appropriate other potential benefits of SNB, including the likelihood of SNB itself reducing the risk of nodal recurrence. This podcast is suitable for Surgeons, Medical Oncologists, General Practitioners and other healthcare professionals. SPEAKERS A/Prof Sydney Ch'ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Senior Surgeon, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (July 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

He is a graduate of the UMDNJ- Robert Wood Johnson Medical School (Rutgers Medical School). He did his residency at the University Of Texas Medical School's Department of Anesthesiology and interventional Fellowship with world-renowned specialist, Professor Michael Cousins, at the Royal North Shore Hospital in Sydney, Australia. Dr. Grover also enjoys his work as a television medical correspondent with Fox news, CNN and has been featured on the Discovery Channel, NBC, ABC, CBS and PBS. In response to his work in Pain Management and humanitarian efforts, he was given a national award at the White House from President Clinton and First Lady Hillary Clinton.

In this TOGA Podcast, Australian medical oncologist, Associate Professor Chee Lee, St George Hospital, Kogarah, is joined by medical oncologist Dr Tristan Barnes, Royal North Shore Hospital, Sydney, and Dr Alex Davis, PhD candidate and medical oncologist at Chris O'Brien Lifehouse, Sydney. They discuss treatment of patients with non-small cell lung cancer with KRAS mutations, the role of co-mutations, and biomarkers that are negative predictors of response. Furthermore, the speakers give an update on current clinical research and approval status of KRAS inhibitors as well as the clinical need for the availability of KRAS inhibitors in Australia.

Sarah Webb is an ICU Nurse Practitioner and was the driving force behind the creation of an ICU NP model of care at Royal North Shore Hospital, Sydney. Sarah has over 18 years experience in Intensive Care where she has worked as a Clinical Nurse Specialist, ICU Clinical Coordinator, ICU Clinical Educator and Resuscitation CNC. She has also worked as a midwife and in aeromedical retrieval. Since 2014, Sarah has been working as an NP in ICU, building the core practice areas of an intensive care NP and promoting the nurse practitioner role. Sarah has completed a Master of Nursing (Intensive Care), a Graduate Diploma of Midwifery and a Master of Nursing (Nurse Practitioner). Sarah has a particular interest empowering nursing to build advanced clinical practice in intensive care. Link to QR Code and contact details:https://nswhealth.sharepoint.com/:b:/s/RNSHICUNPService-NSLHD/EfP0l1xbFHZJgAXJI5zOfzIBxkCnSEkIdAsufDcoTSvaTw

Putting the trial on trial? Not really, but join us and the ludicrously accomplished Prof Simon Finfer (with special guest appearances by his beloved dogs) for this review of all things Clinical Trial. Why we need them, how to design them, what they tell us and what they don't.   Professor Simon Finfer works at Sydney's George Institute, Royal North Shore Hospital and University New South Wales. He has led/co-led many of the last two decade's  landmark clinical trials in icu (fluid administration, glycemic control, steroid use...you name it).  

In this TOGA Podcast, Australian medical oncologist Dr Jenny Lee at Chris O'Brien Lifehouse, Sydney, is joined by medical oncologist Professor Nick Pavlakis, from Royal North Shore Hospital in Sydney and Lisa Briggs, Stage IV lung cancer survivor, Author, Osteopath and Exercise Physiologist who provides her own personal experience after being diagnosed with ALK+ non-small cell lung cancer in 2014. They discuss treatment of patients with non-small cell lung cancer with ALK mutations, the latest updates on ALK targeted therapies, the emergence of resistance, and how the choice of ALK inhibitor should be made between clinician and patient, taking into account potential side-effects, their management and the impact on the particular patient's lifestyle.

The first time most of us heard of monkeypox was in May 2022. The smallpox-like infection appeared to spring from nowhere and make its way through Europe then the Americas, largely within the gay and bisexual community. But the first documented human case of mpox actually occurred in 1970 in Central Africa and it's been endemic ever since. Last year's mpox outbreak eclipsed prior case numbers in just a few months thanks to a newly evolved strain. The count of confirmed cases totalled over 86,000 all around the world and it's a testament to well-coordinated community health in the developed world that the outbreak was reigned in within a few months of the index case in Europe. But alongside this success story, there's also a cautionary tale about global health strategy. Because mpox wasn't taken seriously in endemic countries, an incubator was created for this new strain to emerge. We also discuss the stigma associated with sexually transmitted infections and the pros and cons of applying this label. GuestsDr Vincent Cornelisse FRACGP FAChSHM PhD (Royal Prince Alfred Hospital, Royal North Shore Hospital, Sydney; Kirby Institute, UNSW)Dr Massimo Giola FRACP FAChSHM PhD (Te Whatu Ora, Tauranga, Rotorua)ProductionProduced by Mic Cavazzini DPhil. Recording assistance in Tauranga from Melissa Cox, Mockingbird Music Studios. Editorial feedback kindly provided by Dr Aidan Tan and Dr David Arroyo. Music licenced from Epidemic Sound includes ‘Cocktail by Major Tweaks, ‘Broke No More' by Cushy, ‘Temple of Ruhnha' by ELFL and ‘Razzamatazz' by Jules Gaia. Music courtesy of Free Music Archive includes ‘Out of the Skies, Under the Earth' by Chris Zabriskie, Image by Flashpop licenced from Getty Images. Please visit the Pomegranate Health web page for a transcript and supporting references. Login to MyCPD to record time spent listening and reading supporting materials. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify, Castbox, or any podcasting app. 

Our latest podcast explores the innovative approach of neoadjuvant immunotherapy - administering checkpoint inhibitor immunotherapy before the surgical removal of melanoma. This promising approach is creating a buzz among multidisciplinary clinicians and researchers globally as the potential benefits for melanoma patients are being realised. Although neoadjuvant therapy is well established in oncology, using immunotherapy in melanoma has revolutionised patient outcomes through significant improvements in overall survival rates. In this engaging podcast, MIA's Prof Georgina Long AO leads a discussion with multidisciplinary world leaders in the neoadjuvant space to discuss: the benefits of checkpoint inhibitor immunotherapy the role of the pathologist in the assessment of neoadjuvant tissue the impact of surgical decision-making as neoadjuvant becomes mainstay treatment options for treatment-refractory patients the role of checkpoint inhibitor immunotherapy in non-melanoma skin cancer. The discussion concludes with case studies to summarise key learnings. This podcast is suitable for Medical Oncologists, Oncologists, Surgeons, Pathologists, Dermatologists, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS: Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney KEY CLINICAL TRIALS SWOG PRADO OpACIN-neo NADINA FURTHER EDUCATION The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists Please note that this podcast was accurate at the time of recording (February 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA's Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

In this Podcast, Dr Malinda Itchins, Medical Oncologist at Royal North Shore Hospital, Co-Chair of the Advanced Non-Small Cell Lung Cancer Group for TOGA and the Lung Cancer Chair of COSA, is joined by Professor Stephen Fox, Director of Pathology and Head of the Molecular Pathology Laboratory at the Peter MacCallum Cancer Centre in Melbourne Victoria and Professor Michael Millward, Medical Oncologist and Cancer Council Professor of Clinical Cancer Research School of Medicine, University of Western Australia to discuss NGS panels in lung cancer. They discuss the logistics and other considerations behind choosing and implementing NGS panels and the potential future application of this technology in clinical management of NSCLC. Keen to hear more beyond this podcast? Save the date 19 July 2023 for a f2f workshop in Melbourne discussing the various technologies for molecular testing, considerations for implementation and downstream applications. Registration will be part of TOGA ASM 2023 registrations expected to open by April 2023.

Despite recent advances in management of primary uveal melanoma, more than half of patients develop metastatic disease – often with poor outcomes. New therapeutic approaches to metastatic disease are vital. In this podcast, A/Prof Matteo Carlino interviews fellow Medical Oncologist Prof Georgina Long AO and Ophthalmologist A/Prof Max Conway on our latest understanding of the diagnosis and management of early and advanced uveal melanoma, including: presentation and diagnostic process current treatment options and rationale for local therapy in early melanoma determining which patients are suitable for screening for metastatic disease developing a surveillance plan based on risk of recurrence the different activity of systemic therapy in uveal versus cutaneous melanoma importance of the multidisciplinary team activity of tebentafusp in advanced uveal melanoma the current clinical trial landscape. This podcast is suitable for Oncologists, Ophthalmologists, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals Clinical Associate Professor, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Max Conway - Ophthalmologist, Save Sight Institute, Sydney Eye Hospital and The University of Sydney RESOURCES Early Ocular Melanoma Patient Information Brochure Advanced Ocular Melanoma Patient Information Brochure Melanoma Education Portal Please note that this podcast was accurate at the time of recording (November 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA's Education Program is proudly supported through unrestricted educational grants from MSD, BMS, Novartis and HEINE.

 Dr May Wong a gastroenterologist from Sydney's Royal North Shore Hospital on ways to combat reflux/heartburn. One in five Australians suffers from this. She also tells us the warning signs if it's something more serious.See omnystudio.com/listener for privacy information.

As a new Fellow, Dr Zainab Naseem was hoping to achieve a more comfortable work-life balance when she came across an advertisement for the New Fellow Rural Placement – or NFRP – on the College's website. The NFRP is an initiative delivered by RACS through the Specialist Training Program, funded by the Australian Department of Health. Dr Naseem was at Sydney's Royal North Shore Hospital at the time when she applied for the rural placement at Griffith Base Hospital, in the Riverina region of central New South Wales. Although it was hard to adjust at first, Dr Naseem and her young family have learned to love the regional city.See omnystudio.com/listener for privacy information.

Did you know that 500 million people around the world have osteoarthritis? In those over 55 years of age, a staggering one in three people have osteoarthritis. While many people may well suffer in silence or become isolated from the disease, it's important to recognise that you are not alone in your experience of living with this disease. Professor Lyn March joins us on this episode to discuss the burdn of OA in Australia and worldwide. Professor Lyn March has a conjoint appointment with the University of Sydney and the Royal North Shore Hospital in the Sydney Medical School and Professorial Department of Rheumatology. She has 20 years of experience as a consultant rheumatologist and has remained very active in research and teaching. She has had a lead role in her profession holding Presidential and other honorary executive positions in both the NSW and Australian Rheumatology Associations and is co-chair of the NSW Musculoskeletal Network for the recently formed NSW Health Agency for Clinical Innovation. She is the International Musculoskeletal Expert Group Leader for the current Global Burden of Diseases StudyRESOURCESThe Institute for Health Metrics and EvaluationBurden of osteoarthritis in India and its states, 1990-2019: findings from the Global Burden of disease study 2019CONNECT WITH LYNTwittter: @lynmarch1Australian Arthritis and Autoimmune Biobank CollaborationCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! See acast.com/privacy for privacy and opt-out information.

He is a graduate of the UMDNJ- Robert Wood Johnson Medical School (Rutgers Medical School). He did his residency at the University Of Texas Medical School's Department of Anesthesiology and interventional Fellowship with world-renowned specialist, Professor Michael Cousins, at the Royal North Shore Hospital in Sydney, Australia. Dr. Grover also enjoys his work as a television medical correspondent with Fox news, CNN and has been featured on the Discovery Channel, NBC, ABC, CBS and PBS. In response to his work in Pain Management and humanitarian efforts, he was given a national award at the White House from President Clinton and First Lady Hillary Clinton.

Physical Activity with Osteoarthritis - Prof David Hunter (Pt2) Professor Hunter is a rheumatology clinician researcher whose main research focus has been clinical and translational research in osteoarthritis (OA). He is the Florance and Cope Chair of Rheumatology and Professor of Medicine at University of Sydney and the Royal North Shore Hospital. He is ranked as the worlds leading expert in osteoarthritis on Expertscape.com since 2014. He is on the editorial board for Arthritis and Rheumatology, Osteoarthritis and Cartilage, Arthritis Care and Research and part of the review committee for OA for the American College of Rheumatology, EULAR and OARSI scientific meetings. Dr Hunter has over 500 peer reviewed publications in international journals, numerous book chapters, is the section editor for UpToDate Osteoarthritis and has co-authored a number of books, including books on self management strategies for the lay public. --- This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research --- Collect, store and manage SB and PA data easily and remotely - Discover new Fibion SENS Motion: https://sens.fibion.com/

Professor Hunter is a rheumatology clinician researcher whose main research focus has been clinical and translational research in osteoarthritis (OA). He is the Florance and Cope Chair of Rheumatology and Professor of Medicine at University of Sydney and the Royal North Shore Hospital. He is ranked as the worlds leading expert in osteoarthritis on Expertscape.com since 2014. He is on the editorial board for Arthritis and Rheumatology, Osteoarthritis and Cartilage, Arthritis Care and Research and part of the review committee for OA for the American College of Rheumatology, EULAR and OARSI scientific meetings. Dr Hunter has over 500 peer reviewed publications in international journals, numerous book chapters, is the section editor for UpToDate Osteoarthritis and has co-authored a number of books, including books on self management strategies for the lay public. --- This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research --- Collect, store and manage SB and PA data easily and remotely - Discover new Fibion SENS Motion: https://sens.fibion.com/

Dr. Khairil Musa is a Senior Intensive Care Registrar from Royal North Shore Hospital and an ICU Field Doctor with Doctors Without Borders/Médecins Sans Frontières (MSF). Khairil was deployed to Yemen and Iraq in 2020 as part of MSF's COVID19 response and also worked in MSF's Trauma Hospital in Aden. In his downtime Khairil is passionate about the performing arts and is a classically trained dancer and the Creative Lead for the SMACC/CODA Conference opening ceremonies.In this episode, we discuss his journey into intensive care as a specialty, the application process and deployment for MSF, his work in Yemen and Iraq with MSF, the post-traumatic stress and burnout he suffered, his recovery, and his love for classical ballet. As always, if you have any feedback or queries, or if you would like to get in touch with the speaker, feel free to get in touch at doctornos@pm.me.Audio credit:Bliss by Luke Bergs https://soundcloud.com/bergscloudCreative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0Free Download / Stream: https://bit.ly/33DJFs9Music promoted by Audio Library https://youtu.be/e9aXhBQDT9YSupport the show (https://www.patreon.com/doctornos)

This is part 2 of my chat with Bill Bestic.Bill is a former soldier in the NZ SAS and currently is an Anaesthetist at Royal North Shore Hospital in Sydney and is a recently qualified commercial helicopter pilot.I would recommend listening to Part 1 as it will provide some context to this half of the conversation 

This week I have something a little different, I am joined by Bill Bestic and this session will be broken in to part 1 and part 2 as he was kind enough to spend a fair amount of time with meI have always had a fascination with the SAS and that is how I stumbled across Bill was searching for podcasts with SAS soldiers. I was immediately captivated by Bills humility and his ability to reflect on what he had learnt, take a look at himself first and then evolve his skillsWhat I also found fascinating was once Bill finished in the SAS he trained to become a doctor and then an anaesthetist which he now does at Royal North Shore Hospital in Sydney , oh and also he become a commercial helicopter pilot over the last couple of years too!I was intrigued to dig into the different leadership styles and environments between general population and the military and if there is stuff we could learn from either environment. Bill is a fantastic learner and thinker, there is so much to learn from this episode I trust you will enjoy it and part 2 will come out next week.

In this Healthed lecture, Consultant Psychiatrist from Royal North Shore Hospital, Dr Prachi Brahmbhatt, will explain that the rates of remission and recovery after a single schizophrenic episode are good (~80%), but the rates decline with each subsequent episode. As such, maintaining adherence and optimizing symptom control improves physical health outcomes and this is where GPs have a very important role. Dr Brahmbhatt will provide a very useful, practical guide to choosing, initiating, titrating, balancing effectiveness against tolerability, and switching and monitoring for adverse effects. See omnystudio.com/listener for privacy information.

Dr. Carolyn Lam:               Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. What is the association between fetal congenital heart defects and maternal risk of hypertensive disorders of pregnancy? We will be discussing new data in this area in just a moment, following these summaries.                                                 The first paper describes the effect of long-term metformin and lifestyle measures on coronary artery calcium. This is a paper from Dr. Goldberg of George Washington University Biostatistics Center and colleagues of the Diabetes Prevention Program Research Group. The Diabetes Prevention Program and its outcome study is a long-term intervention study in subjects with prediabetes, which showed reduced diabetes risk with lifestyle and metformin compared to placebo.                                                 In the current study, the authors looked at subclinical atherosclerosis, which was assessed in 2,029 participants using coronary artery calcium measurements after 14 years of average follow-up. They found that men but not women with prediabetes treated with metformin for an average duration of 14 years had lower coronary calcium scores than their placebo counterparts. No difference in coronary calcium scores was observed in the group receiving a lifestyle intervention as compared to the placebo group.                                                 These findings provide the first evidence that metformin may protect against coronary atherosclerosis in men with prediabetes, although demonstration that metformin reduces cardiovascular disease events in these subjects is still needed before firm therapeutic implications of these findings can be made. The reason for an absence of an effect in women is unclear and deserves further study.                                                 The next study provides insights on the physiology of angina from invasive catheter laboratory measurements during exercise. Dr. Asrress of Royal North Shore Hospital in Sydney, Australia, and colleagues, studied 40 patients with exertional angina and coronary artery disease who underwent cardiac catheterization via radial axis and performed incremental exercise using a supine cycle ergometer. As they developed limiting angina, sublingual GTN was administered to half the patients and all patients continued to exercise for two minutes at the same workload. Throughout exercise, distal coronary pressure and flow velocity, and central aortic pressure were recorded using sensor wires.                                                 Using this novel invasive approach, the authors showed that administration of GTN ameliorated angina by reducing myocardial oxygen demand as well as increasing supply with a key component being the reversal of exercise-induced coronary lesion vasoconstriction. This was evidenced by the fact that there was a relationship between the diastolic velocity pressure gradient with significant increase in relative stenosis severity. In keeping with exercise-induced vasoconstriction of stenosed epicardial segments and dilation of normal segments, with trends towards reversal with GTN.                                                 Thus, this study describes the development of a paradigm where patients with coronary artery disease can exercise while simultaneously having coronary and central aortic hemodynamics measured invasively, and has shown that this provides a unique opportunity to study mechanisms underlying the physiology of angina. In treating patients with exercise-induced angina, the results highlight the importance of after-load reduction and the use of agents that reduce arterial wave reflection and promote coronary artery vasodilation.                                                 The next study provides mechanistic insights into reverse cholesterol transport, where excess cholesterol is removed from macrophage-derived foam cells in atherosclerotic plaques. It suggests that melanocortin receptor-1, or MC1-R, may play a role. As background, the melanocortin system, consisting of melanocyte-stimulating hormones and their receptors, regulate a variety of physiological functions, ranging from skin pigmentation to centrally-mediated energy balance control. At the cellular level, the biological actions are mediated by G protein-coupled melanocortin receptors, such as MC1-R. MC1-R not only affects melanogenesis in the skin but also has immunomodulatory effects through its wide expression in the cells of the immune system.                                                 In the current study from Dr. Rinne of University of Turku in Finland, and colleagues, human and mouse atherosclerotic samples and primary mouse macrophages were used to study the regulatory functions of MC1-R. The impact of pharmacological MC1-R activation on atherosclerosis was further assessed in apolipoprotein E deficient mice. Their findings identified a novel role for MC1-R in macrophage cholesterol transport. Activation of MC1-R conferred protection against macrophage foam cell formation through a dual mechanism. It prevented cholesterol uptake while it concomitantly promoted reverse cholesterol transport by increasing the expression of ATP-binding cassette transporters, ABCA1 and ABCG1.                                                 Thus, the identification of MC1-R in lesional macrophages, demonstration of its role in regulating reverse cholesterol transport, combined with its established anti-inflammatory effects, suggests that MC1-R could be a novel new therapeutic target for preventing atherosclerosis.                                                 The next study suggests that obesity-related heart failure with preserved ejection fraction, or HFpEF, is a genuine form of cardiac failure and a clinically relevant phenotype that may require specific treatments. First author, Dr. Obokata, corresponding author, Dr. Borlaug, and colleagues from Mayo Clinic Rochester and Minnesota studied 99 patients with obese HFpEF with a BMI above 35, with 96 non-obese HFpEF with a BMI less than 30, and 71 non-obese controls without heart failure. All subjects underwent detailed clinical assessment, echocardiography, and invasive hemodynamic exercise testing.                                                 The authors found that, compared to non-obese HFpEF, obese HFpEF patients displayed greater volume overload, more biventricular remodeling, greater right ventricular dysfunction, worse exercise capacity, more impaired pulmonary vasodilation, and more profound hemodynamic arrangements, despite a lower NT-proBNP level. Obese HFpEF patients displayed other important contributors to high left ventricular filling pressures, including greater dependence on plasma volume expansion, increased pericardial restraint, and enhanced ventricular interaction, which was exaggerated as pulmonary pressure load increased.                                                 These data provide compelling evidence that patients with the obese HFpEF phenotype have real heart failure and display several pathophysiological mechanisms that differ from non-obese patients with HFpEF. These and other issues are discussed in an accompanying editorial by Dr. Dalane Kitzman and myself. We hope you enjoy it.                                                 The final study identifies a novel long noncoding RNA that regulates angiogenesis. As background, although we know that the mammalian genome is pervasively transcribed, a large proportion of the transcripts do not encode a protein, and are thus regarded as noncoding RNAs. Based on their length, they can be divided into small or long noncoding RNAs, long being described as more than 200 nucleotides. Although their function is not fully understood, long noncoding RNAs have been increasingly reported to mediate the expression of other genes, affect the organization of the nucleus, and modify other RNAs.                                                 In the current study by first author, Dr. Leisegang, corresponding author, Dr. Brandes, and colleagues of Goethe University in Frankfurt, Germany, epigenetically controlled long noncoding RNAs in human umbilical vein endothelial cells were searched by axon array analysis following knockdown of the histone demethylase JARID1B. The authors discovered a novel noncoding RNA named MANTIS to be strongly upregulated. MANTIS is located in the antisense strand of an intronic region of the gene for annexin A4, calcium- and phospholipid-binding protein. MANTIS is a nuclear long noncoding RNA that is enriched in endothelial cells but also expressed in other cell types. Reducing MANTIS levels led to impaired endothelial sprouting, tube formation, attenuated endothelial migration, and inhibition of the alignment of endothelial cells in response to shear stress.                                                 Brahma-like gene 1, or BRG-1, was identified as a direct interaction partner of MANTIS, implying a role of MANTIS in the formation of the switch/sucrose non-fermentable chromatin remodeling complex. MANTIS binding to BRG-1 was shown to stabilize the BRG-1 interaction, hence by inducing an open chromatin conformation, MANTIS was proposed to maintain the endothelial angiogenic potential. The implications of these findings are discussed in an accompanying editorial by Dr. Zampetaki and Mayr from Kings College London.                                                 That brings us to the end of our summaries. Now for our feature discussion.                                                 Today, we are going to be discussing the association between fetal congenital heart defects and maternal risk of hypertensive disorders of pregnancy. To discuss this, I have the first and corresponding author of our feature paper, Dr. Heather Boyd, from Statens Serum Institut in Copenhagen, and our familiar Dr. Sharon Reimold, content editor for special populations from UT Southwestern. Welcome, Heather and Sharon. Dr. Heather Boyd:            Thank you. Dr. Sharon Reimold:        Thank you. Dr. Carolyn Lam:               Heather, it's a topic that I can't say I'm very familiar with, association between fetal congenital heart defects and maternal risk of hypertensive disorders of pregnancy. Could you start by sharing why would we think there would be a link? What was the hypothesis you were testing? Dr. Heather Boyd:            A couple years ago, there was a paper published in the European Heart Journal that reported evidence of angiogenic imbalance in women with fetuses with major congenital heart defects, so women who were pregnant with babies that had heart defects, and then in fetuses that were terminated because of this kind of defect. My research group focuses a lot of attention on preeclampsia. In the last decade or so, angiogenic imbalance in preeclampsia has been a really hot topic. Women with preeclampsia, particularly women with early-onset preeclampsia, have big angiogenic imbalances. When we saw the European Heart Journal paper, we immediately thought, "What's the connection between preeclampsia and heart defects in the offspring?" Dr. Carolyn Lam:               Oh! Dr. Heather Boyd:            Exactly. That was our entry point to it, was the term "angiogenic imbalance" in that paper sort of was a flag for us. It wasn't a completely new idea, but we in Denmark have one big advantage when considering research questions that involve either rare exposures and/or rare outcomes, and that's our National Health Registry. We have the ability to assemble these huge cohorts and study conditions like heart defects with good power, so we decided just to go for it. Dr. Carolyn Lam:               That makes a lot of sense now. Please, tell us what you did and what you found. Dr. Heather Boyd:            The first thing we did was look at the association between carrying a baby with a heart defect and then whether the mom had preeclampsia later in the same pregnancy. We had information on almost 2 million pregnancies for this part of the study. We found that women carrying a baby with a heart defect were seven times as likely as women with structurally normal babies to develop early preterm preeclampsia. We defined that as preeclampsia where the baby has to be delivered before 34 weeks, so the really severe form of preeclampsia. Then, women carrying a baby with a heart defect were almost three times as likely to develop late preterm preeclampsia as well. That's where they managed to carry it until 34 weeks but it has to be delivered some time before 37 weeks.                                                 These findings were similar to those of other studies, but we were able to go a step further and look at individual heart defect subtypes. What we found there waws that these strong associations were similar across defect categories. Then we decided to see if we could shed any light on the origin of the problem, whether it was coming from the mom's side or the baby's side. To do this, we looked at women with at least two pregnancies in our study period to see whether preeclampsia in one pregnancy had any bearing on the chance of having a baby with a heart defect in another pregnancy or vice versa.                                                 This part of the study included 700,000 women. We found very similar findings. We found that women with early preterm preeclampsia in one pregnancy had eight times the risk of having a baby with a heart defect in a subsequent pregnancy. Late-term preeclampsia in one pregnancy was associated with almost three times the risk of offspring heart defects in later pregnancies. Then, we found that it worked the other way around too. Women who had a baby with a heart defect were twice as likely to have preterm preeclampsia in subsequent pregnancies.                                                 Those results were really, really exciting, because whatever mechanisms underlie the associations between preterm preeclampsia in moms and heart defects in the babies, they operate across pregnancies. Therefore, that pointed towards something maternal in origin. Dr. Carolyn Lam:               That is so fascinating. Sharon, please, share some of the thoughts, your own as well as those of the editors when we saw this paper. Dr. Sharon Reimold:        I think that there's a growing data about the links between hypertensive disorders of pregnancy and preeclampsia with subsequent abnormal maternal outcome. But this paper, I think, has implications for how we look at moms who are going to have offspring with congenital heart defects as well as those with preeclampsia. For instance, I would look at a patient now that has preeclampsia, especially in more than one pregnancy, to identify that they may be at risk to have offspring with congenital defects in the future if they have additional children. But the mom is also at risk based on other data for developing other cardiovascular risk factors and disease as she gets older. It was really the link going back and forth with the hypertensive disorders and the congenital defects that we found the most interesting. Dr. Carolyn Lam:               That struck me too, especially when you can look at multiple pregnancies and outcomes. That's amazing. You know what, Heather, could you share a little bit about what it's like working with these huge Danish databases? I think there must be a lot more than meets the eye. Dr. Heather Boyd:            It's an interesting question, because I'm a Canadian and I was trained in the US. I did my PhD in epidemiology at Emery, and then I moved to Copenhagen. When I first got here, I was absolutely floored at the possibility of doing studies with millions of women in them. It opens some amazing possibilities, like I said earlier, for certain outcomes and certain exposures. You just need to have a question where the information you want is registered. Dr. Carolyn Lam:               Yeah. But I think what I also want to put across is, having worked with big databases, and certainly not as big as that one, it's actually a lot of work. People might think, "Oh, it's just all sitting there." But, for example, how long did it take you to come to these observations and conclusions? Dr. Heather Boyd:            I have a fabulous statistician. I think she's the second author there, Saima Basit. She spends a lot of her time pulling together data from different registers. But yes, you're right. The data don't always just mesh nicely. The statisticians we have working with us are real pros at this sort of data slinging. Dr. Carolyn Lam:               Could I just pose one last question to both of you. What do you think are the remaining gaps? Dr. Sharon Reimold:        I think that this is a clinical link. Then, going back to figure more about what's going on biologically to set up this difference? Because right now there's really no intervention that's going to make a difference, it's just a risk going forward. This is sort of like medicine done backwards, that there's this association and now we need to figure out exactly why. Dr. Heather Boyd:            I can piggyback on what Sharon said a little bit, because I think one of the things we need to remember is that not all women with preeclampsia have babies with heart defects. Not by a long shot. What we need to do now is to figure out what distinguishes the women who do get this double whammy from the vast majority who don't.                                                 One of the things that Denmark does really nicely is that there are large bio banks. One of the things we want to do is go back to bank first trimester maternal blood samples and see if we can identify biomarkers that are unique to the women with both preterm preeclampsia and babies with heart defects. That's one of the things we're thinking about to address this gap. Because, as Sharon says, we've got to figure out what the mechanism is.                                                 The other thing we want to do is to see whether the association between preeclampsia and heart defects extends, for example, to other things, to cardiac functional deficits, for example, because it's probably not just severe structural defects. If there's an association, it's probably on a continuum. Are babies born to preeclamptic moms, do their cardiac outputs differ? Do their electrical parameters differ? Do they just have different hearts?                                                 We're really lucky because right now the Copenhagen Baby Heart Study is offering to scan the hearts of all infants born at one of the three major university hospitals in the Copenhagen area. We're about to have echocardiography data on 30,000 newborn hearts to help us look at this. I'm really excited about that possibility. Dr. Carolyn Lam:               I've learnt so much from this conversation. I'm sure the listeners will agree with me. Thank you both very, very much.

Infectious bacteria are becoming resistant to the drugs that used to kill them. The last new class of antibiotics was discovered in the 1980s. There is little in the development pipelines of the world's pharmaceutical industry. Drug companies got out of antibiotics as their attention switched to much more lucrative daily medicines for chronic diseases. Public funding on antibiotic research has also withered. Now that the gathering crisis of antibiotic resistance is becoming recognised by politicians, what are the options? Roland Pease explores how business, academia and governments might work together to avert a return to the medical dark ages.Image Credit: Hospital scientist inspects an unidentified culture in the Microbiology Department of Sydney's Royal North Shore Hospital, Greg Wood/AFP/Getty Images

The discovery and harnessing of antibiotic drugs in the mid-20th Century led some medics to predict the end of infectious diseases. But the bacteria fought and continue to fight back, evolving resistance to many of the drugs that used to kill them. Public health officials warn that without new drugs, medicine will return to the days where ‘a cut finger on Monday leads to death of Friday'. Without protective antibiotics to keep infections at bay, scores of standard surgical operations and chemotherapy for cancer will become too risky.Roland Pease looks at scientific issues behind the gathering crisis. The last new class of antibiotics was discovered in the 1980s. Are there any others in the pipeline?Image Credit: Hospital scientist inspects an unidentified culture in the Microbiology Department of Sydney's Royal North Shore Hospital, Greg Wood/AFP/Getty Images